Additional file 2: of Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Karzai, Fatima; VanderWeele, David; Madan, Ravi; Owens, Helen; Cordes, Lisa; Hankin, Amy; Couvillon, Anna; Nichols, Erin; Bilusic, Marijo; Beshiri, Michael; Kelly, Kathleen; Krishnasamy, Venkatesh; Lee, Sunmin; Lee, Min-Jung; Yuno, Akira; Trepel, Jane; Merino, Maria; Dittamore, Ryan; MartĂŠ, Jennifer; Donahue, Renee; Schlom, Jeffrey; Killian, Keith; Meltzer, Paul; Steinberg, Seth; Gulley, James; Lee, Jung-Min; Dahut, William

doi:10.6084/m9.figshare.7422335.v1

40425_2018_463_MOESM2_ESM.docx (18.52 kB)

Additional file 2: of Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

journal contribution

posted on 2018-12-04, 05:00 authored by Fatima Karzai, David VanderWeele, Ravi Madan, Helen Owens, Lisa Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane Trepel, Maria Merino, Ryan Dittamore, Jennifer MartĂŠ, Renee Donahue, Jeffrey Schlom, Keith Killian, Paul Meltzer, Seth Steinberg, James Gulley, Jung-Min Lee, William Dahut

A. Immunophenotyping of myeloid-derived suppressor cells (MDSCs). B. Statistical analysis of pharmacodynamic endpoints. (DOCX 18 kb)